Navigation Links
Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar

Tracy Worzella and Brad Larson
Promega Corporation, Madison, WI, USA


Application Note 138 Rev. 07/2006

  • Correlated measurement of an apoptosis marker (or caspase activity) and cell viability
  • Monitoring of both luminescence and fluorescence output signals from one assay well
  • Assay miniaturization up to 1536-well format

  • Introduction
    Today's high-throughput screening facilities face increasing demands to generate more information from their existing compound libraries. One method of obtaining this information is to run assays sequentially, looking at one parameter followed by another in different plates. While this option may produce the desired data, the increased time and consumable costs are drawbacks. A more appealing method for data generation is to perform assays in a multiplexed format in which several parameters can be measured within the same well. This multiplexed format not only saves time and consumable cost, but also saves on valuable test compounds.

    This concept of assay multiplexing is demonstrated here using several cell-based assays multiplexed together. There are inherent properties to cell assays that make them attractive for multiplexed cell-based applications. Cell-based assays are especially vulnerable to variations due to differences in cell growth and metabolism that can arise from plate-to-plate. Cell culture itself is also expensive. By multiplexing assays, fewer cells are needed to acquire the same amount of data. Using the same cells for subsequent assays can also ensure more precise data. In this application note, we demonstrate the combination of several Promega cell-based assays multiplexed in both low-volume 384 and 1536-well plate formats. The BMG LABTECH PHERAstar microplate reader is used to record both luminescence and fluorescence, depending on the multiplex combination. Table 1 highlights the assays used in this application.


    Materials and Methods

  • Jurkat cells
  • Anti-FAS monoclonal antibody
  • Corning Low-volume 384-well plates, catalog no. 3673
  • Corning 1536-well plates, catalog no. 3937
  • Promega Caspase-Glo 3/7 Assay System, catalog no. G8091*
  • Promega CellTiter-Blue Cell Viability Assay, catalog no. G8080
  • Promega Apo-ONE Homogeneous Caspase 3/7 Assay, catalog no. G7790
  • Deerac Fluidics Equator HTS low-volume liquid dispenser
  • BMG LABTECH PHERAstar (figure 1)
  • BMG LABTECH PHERAstar luminescence optic module
  • BMG LABTECH PHERAstar fluorescence optic module (Ex: 485 nm; Em: 520 nm)
  • BMG LABTECH PHERAstar fluorescence optic modules (Ex: 540 nm; Em: 590 nm)

  • Multiplexing Cell Viability and Apoptosis Assays
    Promegas fluorescent CellTiter-Blue cell viability assay was multiplexed with either the luminescent Caspase-Glo 3/7 assay, or the fluorescent Apo-ONE assay. The experimental set-up was similar for each assay combination.

    For the low-volume 384 assay format, a density of 10,000 Jurkat cells per well was plated with the Deerac Fluidics Equator. Next, a range of anti-FAS monoclonal antibody was added to the plate, with the final concentration per well ranging from 400 ng/mL down to 0 ng/mL of antibody. The plates were then incubated at 37C / 5% CO2 for a total of 5 hours to induce apoptosis. 3 hours into the 5 hour treatment, CellTiter-Blue reagent was added to each well with the Equator (note: for plates later receiving Caspase-Glo 3/7 reagent, CellTiter-Blue was diluted 1:4 in 1X PBS before addition to the assay plate). After the CellTiter-Blue addition, plates were incubated for 2 hours at 37C / 5% CO2. When the 5 hour incubation with anti-FAS antibody was complete, fluorescence was recorded at excitation 540 nm and emission of 590 nm with the PHERAstar. The caspase reagents were then added to the plates with the Equator. Apo-ONE was added to one plate containing CellTiter-Blue reagent, and the plate was incubated at room temperature for 1 hour, followed by fluorescence reading with the PHERAstar at excitation 485 nm and emission of 520 nm. Caspase-Glo reagent was added to the plate receiving the diluted CellTiter-Blue reagent, and incubated for 1 hour at room temperature. Luminescence was then recorded with the PHERAstar.

    For the 1536-well assay format, a density of 4,000 cells per well was plated with the Deerac Fluidics Equator. The remaining multiplex protocols were performed identically to the low-volume 384 protocols listed above.


    Results and Discussion
    Promegas CellTiter-Blue assay multiplexed with either Caspase-Glo 3/7 (figure 2) or Apo-ONE assay was prepared in both low-volume 384- and 1536-well format (figure 3). Cell viability and apoptosis were sequentially measured with BMG LABTECHs PHERAstar in both luminescence and fluorescence modes, depending on the multiplex combination. Jurkat cells were treated with various concentrations of anti-FAS monoclonal antibody for 5 hours to induce apoptosis. Cell viability was determined by adding CellTiter-Blue reagent to each well after drug addition and incubating for two hours before recording fluorescence (Ex: 540 nm; Em: 590 nm). The caspase activity was then measured by adding either Caspase-Glo 3/7 or Apo-ONE reagent and incubating for an additional hour prior to recording luminescence or fluorescence (Ex: 485 nm; Em: 520 nm) respectively.

    Figures 2 and 3 show the results of two experiments to determine the method of cell death caused by different concentrations of anti-FAS antibody in Jurkat cells. The two experiments measured two different endpoints: reduction of a resazurin dye as an indicator of viable cells and caspase activity as a marker for apoptotic cells. The data show that with increasing concentration of anti-FAS antibody, an increase in caspase-3/7 activity, with a corresponding decrease in cell viability, is observed.



    The results suggest that the cell population studied is less viable over the range of treatment due to an increase in apoptosis, as opposed to necrosis.For all cell viability and apoptosis multiplexing combinations, results in 1536 format are comparible to results in 384-well format.


    Conclusion
    Each of the experiments shown here highlights the ability to perform different assays within the same assay well. Using a non-lytic assay first, such as the CellTiter-Blue assay used here, allows for the sequential multiplexing of several different reagents within the same well. Multiplexed cell-based assays allow for multiple parameters to be measured within the same well. One example of this is to determine the method of cell death following a certain treatment protocol. By performing two assays within the same well, information on mode of action of drugs could be obtained faster and with less consumable usage. Data from miniaturized assays in 1536-well format are comparable to those run in low volume 384, indicating that smaller assay volume does not compromise the results obtained in higher density formats. The data generated here also showcases the ability of BMG LABTECHs multifunctional PHERAstar to record multiple output signals from the same assay well.


    * See Promegas website for patent marking information
    www.promega.com


    back to top


    '"/>

    Source:


    Page: All 1 2 3 4 5

    Related biology technology :

    1. Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar
    2. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
    3. Cell Proliferation and Viability Measurement
    4. LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43)
    5. RT-PCR Primers for the Study of Apoptosis
    6. A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage
    7. Apoptosis detection by annexin V and active caspase-3 with the Agilent 2100 bioanalyzer
    8. Caspase-3 Activation - An Indicator of Apoptosis in Image-Based Assays
    9. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
    10. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
    11. Using Validated siRNAs in Functional Genomic Assays
    Post Your Comments:
    (Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
    (Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
    (Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
    (Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
    Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
    ... Age of Unreason," an important book in which author ... business-affecting change. Though an economist, Handy could not have ... our current recession, yet he offers a prescient perspective ... a shift from manufacturing- to a knowledge-based economy. , ...
    ... challenging, but knowing how to conduct the proper interviews can ... getting the right person. If its a top executive position ... of the candidates background is critical, but having a method ... experiences increases the chances of hiring the right person. ...
    ... Catalyst International, a global provider of supply ... of platform-independent SCE applications. , ,"We're expanding and ... increasing demand for integrated fulfillment solutions from supplier ... said Jim Treleaven, President and CEO of Catalyst. ...
    Cached Biology Technology:The Molecular Organization 2The Molecular Organization 3Improving the Hiring Process 2
    (Date:7/11/2014)... release is available in German . ... a method that uses the refraction of X-rays through ... images produced with this method are often of much ... in the team of Prof. Franz Pfeiffer are particularly ... and therapy including X-ray phase-contrast imaging. One main ...
    (Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
    (Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
    Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
    ... first comprehensive multi-model-based assessment of so-called Durban Platform scenarios, ... the Potsdam Institute for Climate Impact Research (PIK) and ... Durban Platform is the current negotiation track at the ... climate agreement by 2015 to come into effect in ...
    ... developing a comprehensive data system that can be used ... them with access to chemical toxicity information. ... the "automated profiling system" from existing bioassay data from ... help scientists who are seeking information on chemicals of ...
    ... continues to support the role of protein in building and ... embracing the important role of protein in the diet. ... out that protein quality really does matter. The latest ... at SupplySide West, the leading destination for the exploration, discovery, ...
    Cached Biology News:Success of climate talks vital for 2°C target 2Success of climate talks vital for 2°C target 3Toxicity database under development at Rutgers-Camden 2Protein quality: It matters 2Protein quality: It matters 3
    Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
    Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
    PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
    Pendrin (H-195)...
    Biology Products: